Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Durvalumab and Guadecitabine in Advanced Kidney Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03308396
Recruitment Status : Recruiting
First Posted : October 12, 2017
Last Update Posted : February 1, 2019
Sponsor:
Collaborators:
AstraZeneca
Big Ten Cancer Research Consortium
Information provided by (Responsible Party):
Ajjai Alva, MD, Big Ten Cancer Research Consortium

Brief Summary:
This is a single arm, multi-centre (via Big Ten Cancer Research Consortium) phase Ib/II study of patients treated with durvalumab 1500 mg IV q 4 weeks in combination with guadecitabine at the recommended phase 2 dose subcutaneously for 5 consecutive days. Eligible patients will have metastatic RCC with a clear cell component, ECOG performance status of 0-1, have received 0-1 prior therapy but no prior anti-PD-1/PD-L1/CTLA4 (Cohort 1, 36 subjects). Study treatment could potentially continue for up to 13 cycles (52 weeks).

Condition or disease Intervention/treatment Phase
Advanced Kidney Cancer Kidney Cancer Clear Cell Renal Cell Carcinoma Drug: Guadecitabine Drug: Durvalumab Phase 1 Phase 2

Detailed Description:

A total of up to 58 subjects will be enrolled on both phases.

Phase Ib: 6-12 subjects; enrolled into either Cohort 1 or 2. Phase II: 46 subjects; enrolled into either Cohort 1 or 2.

Cohort 1 (36 subjects): received 0-1 prior therapy and no prior anti-PD-1/PD-L1/CTLA4.

Cohort 2 (16 subjects): received up to 2 prior therapies, one of which must include an anti-PD-1/PD-L1 therapy to which they did not respond. Only one prior anti-PD-1/PD-L1 therapy is allowed.

Patients from Phase Ib treated at the eventual phase II dose will be combined with patients in Phase II in the efficacy analysis.

  • Therapy will start with guadecitabine on days 1-5 of a 28-day cycle. Guadecitabine will be dosed subcutaneously on days 1-5 at either dose level 0 (60 mg/m2) or dose level -1 (45 mg/m2), based on the recommended phase II dose.
  • Durvalumab will be started on day 8 of the 28-day cycle. Durvalumab will be administered intravenously at a flat dose of 1500mg every 28 days.
  • Study treatment may continue for up to 13 cycles (52 weeks) in the absence of confirmed progression, intolerable toxicity, or withdrawal of consent.

Phase Ib Treatment Plan

  • Dose limiting toxicities (DLTs) will be evaluated within the first cycle (i.e., within the first 28 days).
  • Six patients will be enrolled at dose level 0. If 2 or fewer patients experience a dose limiting toxicity, the study will continue to the phase II portion at dose level 0.
  • Alternately, if 3 or more patients have a dose limiting toxicity at dose level 0, 6 patients will be accrued at the lower dose (dose -1). If 2 or fewer patients experience a dose limiting toxicity, the study will continue to phase II at dose level -1.
  • If 3 or more subjects experience a dose limiting toxicity at dose level -1, the treatment will be considered unsafe and the trial will be stopped. In this case, durvalumab and guadecitabine will be permanently discontinued and the subjects followed per protocol.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 58 participants
Intervention Model: Single Group Assignment
Intervention Model Description: Phase Ib/II
Masking: None (Open Label)
Masking Description: Open-label
Primary Purpose: Treatment
Official Title: Single Arm Phase Ib/II Study of Durvalumab and Guadecitabine in Advanced Kidney Cancer: Big Ten Cancer Research Consortium BTCRC-GU16-043
Actual Study Start Date : December 19, 2017
Estimated Primary Completion Date : December 1, 2019
Estimated Study Completion Date : December 1, 2020


Arm Intervention/treatment
Experimental: Single Arm

This is a non-randomized, single arm, open label Phase Ib/II study.

Phase Ib:

Days 1-5

Guadecitabine:

  • Dose 0: 60 mg/m^2
  • Dose -1: 45 mg/m^2

Phase II:

Days 1-5 Guadecitabine (at Ph II dose)

Day 8 Durvalumab (1500 mg IV) Day 8 Durvalumab (1500 mg IV)

Drug: Guadecitabine
Days 1-5 Dose 0: 60 mg/m^2 Dose -1: 45 mg/m^2
Other Name: SGI-110

Drug: Durvalumab
Day 8 Durvalumab (1500 mg IV)
Other Name: MEDI4736




Primary Outcome Measures :
  1. Phase Ib: Dose limiting toxicities will be assessed to determine if the trial is stopped before the Phase II portion. [ Time Frame: 28 days/First cycle ]
    Number of patients with dose-limiting toxicity (DLT) of the combination of durvalumab and guadecitabine

  2. Objective response rate [ Time Frame: 1 year ]
    Objective response rate (complete response (CR) + partial response (PR)) by RECIST 1.1 in Cohort 1


Secondary Outcome Measures :
  1. Phase II: Overall Survival (OS) [ Time Frame: 2 years ]
    will be reported with 95% confidence intervals from the Kaplan-Meier estimates.

  2. Phase II: Duration of Response (DoR) [ Time Frame: 2 years ]
    will be assessed using Kaplan-Meier estimates including the 95% confidence band separately for cohort 1 and for cohort 2.

  3. Phase II: Progression-free survival (PFS) [ Time Frame: 2 years ]
    will be assessed using Kaplan-Meier estimates including the 95% confidence band separately for cohort 1 and for cohort 2.

  4. Phase II: Clinical benefit rate (CBR) [ Time Frame: 2 years ]
    reported as binomial proportions and corresponding 95% binomial confidence intervals separately for cohort 1 and cohort 2

  5. Phase II: Complete response (CR) proportion [ Time Frame: 2 years ]
    reported as binomial proportions and corresponding 95% binomial confidence intervals separately for cohort 1 and cohort 2

  6. Phase II: Objective Response Rate (ORR) [ Time Frame: 2 years ]
    reported as binomial proportions and corresponding 95% binomial confidence intervals separately for cohort 1 and cohort 2

  7. Phase II: Assess Adverse Events [ Time Frame: 2 years ]
    by CTCAE ver 4 including events of special interest such as immune mediated toxicities



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Subject must meet all of the following applicable inclusion criteria to participate in this study:

  • Written informed consent and HIPAA authorization for release of personal health information.
  • ECOG Performance Status 0-1 within 28 days prior to registration.
  • Histological diagnosis of clear cell renal cell carcinoma (pure or mixed) with radiologic or histologic evidence of metastatic disease.
  • At least 1 lesion, not previously irradiated that can be accurately measured at baseline as ≥ 10 mm in the longest diameter (except lymph nodes which must have a short axis ≥ 15mm) with a computed tomography (CT) or magnetic resonance imaging (MRI) and that is suitable for accurate repeated measurements as per Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1) guidelines.
  • For cohort 1, subjects may have received up to 1 and no more than 1 prior line of systemic therapy (not counting any neoadjuvant/adjuvant therapy) including anti-VEGF, VEGFR inhibitor, MET inhibitor or mTOR inhibitor for metastatic disease. They cannot have received any prior anti-PD-1/PD-L1/CTLA4 therapy including durvalumab.
  • For cohort 2, subjects may have received up to 2 prior systemic therapies which should include 1 (and only 1) prior anti-PD-1/PD-L1 therapy but did not have an objective response to the prior anti-PD-1/Pd-L1 therapy. The treating investigator must document that the patient did not have an objective response to prior anti-PD-1/PD-L1 therapy. They may have received prior anti-CTLA4 therapy.
  • Subjects may not have had radiotherapy treatment to more than 30% of the bone marrow or with a wide field of radiation within 4 weeks of the first dose of study drug.
  • Prior cancer treatment must be completed at least 14 days prior to study registration and the subject must have recovered from all reversible acute toxic effects of the regimen (other than alopecia) to ≤Grade 1 or baseline.
  • Demonstrate adequate organ function as defined in the table below; all screening labs to be obtained within 28 days prior to registration:

Hematological:

  • White blood cell (WBC) ≥ 3 K/mm^3
  • Absolute Neutrophil Count (ANC) ≥ 1.5 K/mm^3
  • Hemoglobin (Hgb) ≥ 9 g/dL
  • Platelets (Plt) ≥ 100,000/mm^3

Renal:

  • Calculated creatinine clearance ≥ 40 cc/min using the Cockcroft-Gault formula

Hepatic:

  • Bilirubin ≤ 1.5 × upper limit of normal (ULN)
  • Aspartate aminotransferase (AST) ≤ 2.5 × ULN
  • Alanine aminotransferase (ALT) ≤ 2.5 × ULN

    • Females of childbearing potential must have a negative serum pregnancy test within 28 days prior to registration.
    • Females of childbearing potential and males must be willing to abstain from heterosexual activity or to use at least 1 highly effective methods of contraception from the time of informed consent until 30 days after treatment discontinuation. The two contraception methods can be comprised of two barrier methods, or a barrier method plus a hormonal method.
    • Life expectancy ≥ 12 weeks (in the opinion of the Investigator)
    • Body weight >30kg
    • Subject is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up.

Exclusion Criteria:

Subjects meeting any of the criteria below may not participate in the study:

  • Active infection requiring systemic therapy.
  • Brain metastases or spinal cord compression. Patients with suspected brain metastases at screening should have an MRI (preferred) or CT each preferably with IV contrast of the brain prior to study entry. Patients whose brain metastases have been treated may be considered if they have completed their treatment for brain metastasis at least 4 weeks prior to study registration provided they show radiographic stability (defined as 1 brain image, obtained after treatment to the brain metastases). In addition, any neurologic symptoms that developed either as a result of the brain metastases or their treatment must have resolved or be stable without the use of steroids for at least 14 days prior to the start of treatment.
  • Pregnant or breastfeeding
  • History of another primary malignancy except for:

    • Malignancy treated with curative intent and with no known active disease ≥5 years before the first dose of IP and of low potential risk for recurrence.
    • Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease.
    • Adequately treated carcinoma in situ without evidence of disease.
  • Treatment with any investigational drug within 14 days prior to study registration.
  • Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease [e.g., colitis or Crohn's disease], diverticulitis [with the exception of diverticulosis], celiac disease, irritable bowel disease, or other serious gastrointestinal chronic conditions associated with diarrhea, systemic lupus erythematosus, sarcoidosis syndrome, or Wegener syndrome [granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc]) within the last 3 years prior to study registration. The following are exceptions to this criterion: The following are exceptions to this criterion:

    • Subjects with vitiligo or alopecia.
    • Subjects with hypothyroidism (eg, following Hashimoto syndrome) stable on hormone replacement.
    • Any chronic skin condition that does not require systemic therapy.
    • Subjects without active disease in the last 5 years may be included but only after consultation with the study physician.
    • Subjects with celiac disease controlled by diet alone.
  • Current or prior use of immunosuppressive medication within 28 days before the first dose of durvalumab, with the exceptions of intranasal and inhaled corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of prednisone, or an equivalent corticosteroid. The following are exceptions to this criterion:

    • Intranasal, inhaled, topical steroids, or local steroid injections (eg, intra articular injection).
    • Systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or its equivalent.
    • Steroids as premedication for hypersensitivity reactions (eg, CT scan premedication).
  • Involvement in the planning and/or conduct of the study (applies to both AstraZeneca/ MedImmune staff and/or staff at the study site).
  • Concurrent enrollment in another clinical study, unless it is an observational (non-interventional) clinical study or during the follow-up period of an interventional study.
  • Any concurrent chemotherapy, biologic or hormonal therapy for cancer treatment. Concurrent use of hormonal therapy for non-cancer-related conditions (e.g. hormone replacement therapy) is acceptable. Note: Local treatment of isolated lesions, excluding target lesions, for palliative intent is acceptable (e.g., local surgery or radiotherapy).
  • Major surgical procedure (as defined by the Investigator) within 28 days prior to study registration. Note: local surgery of isolated lesions for palliative intent is acceptable.
  • History of allogenic organ transplantation that requires use of immunosuppressive agents.
  • Uncontrolled intercurrent illness including but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, interstitial lung disease, or psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring AEs or compromise the ability of the patient to give written informed consent.
  • History of leptomeningeal carcinomatosis.
  • Active infection including tuberculosis (clinical evaluation that includes clinical history, physical examination and radiographic findings), hepatitis B (known positive HBV surface antigen (HBsAg) result), hepatitis C, or human immunodeficiency virus (positive HIV 1/2 antibodies). Subjects with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody [anti-HBc] and absence of HBsAg) are eligible. Subjects positive for hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA.
  • Receipt of live attenuated vaccine within 30 days prior to the first dose of study drug. Note: patients, if enrolled, should not receive live vaccine during the study and up to 30 days after the last dose of study drug.
  • Female patients who are pregnant or breastfeeding or male or female patients of reproductive potential who are not willing to employ effective birth control from screening to 90 days after the last dose of study drug.
  • Known allergy or hypersensitivity to study drugs or other humanized monoclonal antibodies.
  • Patient ≤30kg in weight.
  • Mean QT interval corrected for heart rate (QTc) ≥470 ms calculated from 3 electrocardiograms (ECGs) using Fridericia's Correction.
  • Any unresolved toxicity NCI CTCAE Grade ≥2 from previous anticancer therapy with the exception of alopecia, vitiligo, and the laboratory values defined in the inclusion criteria:

    • Subjects with Grade ≥2 neuropathy will be evaluated on a case-by-case basis after consultation with the Study Physician.
    • Subjects with irreversible toxicity not reasonably expected to be exacerbated by treatment with durvalumab may be included only after consultation with the Study Physician.
  • Past medical history of ILD, drug-induced ILD, radiation pneumonitis which required steroid treatment, or any evidence of clinically active interstitial lung disease.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03308396


Contacts
Layout table for location contacts
Contact: Dana Musapatika 317.634.5842 ext 39 dmusapatika@bigtencrc.org
Contact: Ajjai Alva, M.D. 734-936-0091 ajjai@med.umich.edu

Locations
Layout table for location information
United States, Illinois
Univerisity of Illinois Cancer Center Recruiting
Chicago, Illinois, United States, 60612
Contact: Erin Vidra    312-996-7902    evidra@uic.edu   
Principal Investigator: David Peace, MD         
United States, Iowa
University of Iowa Hosptials and Clinics Recruiting
Iowa City, Iowa, United States, 52242
Contact: Marian Anderson    319-353-4578    marian-andersen@uiowa.edu   
Principal Investigator: Yousef Zakharia, MD         
United States, Michigan
University of Michigan Comprehensive Cancer Center Recruiting
Ann Arbor, Michigan, United States, 48109
Contact: Ajjai Alva, M.D.    734-936-0091    ajjai@umich.edu   
Contact: Carolina Fernandez-Castillo    734-763-8373    cefernan@med.umich.edu   
United States, New Jersey
Rutgers Cancer Institute of New Jersey Recruiting
New Brunswick, New Jersey, United States, 08903
Contact: Daniel Bell    732-235-9850    dwb90@cinj.rutgers.edu   
Principal Investigator: Eric Singer, MD         
United States, Pennsylvania
Penn State Cancer Institute Recruiting
Hershey, Pennsylvania, United States, 17033
Contact: Sean Fleming    717-531-5364    sfleming1@pennstatehealth.psu.edu   
Principal Investigator: Monika Joshi, MD         
Sponsors and Collaborators
Ajjai Alva, MD
AstraZeneca
Big Ten Cancer Research Consortium
Investigators
Layout table for investigator information
Study Chair: Ajjai Alva, M.D. University of Michigan

Additional Information:
Layout table for additonal information
Responsible Party: Ajjai Alva, MD, Sponsor-Investigator, Big Ten Cancer Research Consortium
ClinicalTrials.gov Identifier: NCT03308396     History of Changes
Other Study ID Numbers: BTCRC-GU16-043
First Posted: October 12, 2017    Key Record Dates
Last Update Posted: February 1, 2019
Last Verified: January 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Ajjai Alva, MD, Big Ten Cancer Research Consortium:
Durvalumab
Guadecitabine

Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma, Renal Cell
Kidney Neoplasms
Adenocarcinoma
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Urologic Neoplasms
Urogenital Neoplasms
Neoplasms by Site
Kidney Diseases
Urologic Diseases
Durvalumab
Guadecitabine
Azacitidine
Antibodies, Monoclonal
Antineoplastic Agents, Immunological
Antineoplastic Agents
Immunologic Factors
Physiological Effects of Drugs
Antimetabolites, Antineoplastic
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Enzyme Inhibitors